Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors | MicrobiomeTrials← Back to trialsNCT03627403
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
TERMINATEDPHASE2INTERVENTIONAL
Trial Details
Start: 2019-05-10Est. Completion: 2023-08-16
Enrollment target: 17 participants Locations- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in
Uterine Cervix Cancer
The goal of this clinical trial is to investigate the use of hypofractionated radiation (delivery of fewer but larger do…
Lexington, United StatesEst. completion Jul 1, 2026
Minimal Change Disease (MCD)Membranous NephropathyGlomerulosclerosis, Focal Segmental
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an en…
Los Angeles, United StatesEst. completion Dec 31, 2030
Phase 2
Completed
Myeloproliferative NeoplasmChronic Neutrophilic LeukemiaMDS
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in…
Tampa, United StatesCompleted Apr 10, 2025